1. Home
  2. Live Updates
  3. Uvenile idiopathic arthritis

Live Breaking News & Updates on Uvenile idiopathic arthritis

Stay informed with the latest breaking news from Uvenile idiopathic arthritis on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Uvenile idiopathic arthritis and stay connected to the pulse of your community

Two Biosimilars Approved in Europe for Autoimmune Disorders

The drugs are intended to treat several types of arthritis, psoriasis, COVID-19, and Crohn's disease.

Ukraine , China , Bulgaria , Poland , Georgia , United-states , European-union , Medicinal-products , Human-use , European-medicines-agency , Rheumatoid-arthritis-ra

How play helped girl with arthritis to laugh again

Sfiyah was diagnosed with juvenile idiopathic arthritis when she was just nine.

Parvina-khan , Uvenile-idiopathic-arthritis , Ia , Ctive-child ,

Sub-Q Tocilizumab Gives Durable Long-Term Responses in JIA

Patients with juvenile idiopathic arthritis achieved long-term disease control with subcutaneous tocilizumab treatment, without any new safety concerns, in an LTE study of two trials.

Cincinnati , Ohio , United-states , Herminei-brunner , International-league , Cincinnati-children , Hospital-medical-center , Juvenile-rheumatoid-arthritis , Uvenile-ra , Uvenile-idiopathic-arthritis , Arthritis

Tocilizumab Withdrawal Post Remission in Still's Disease

Longer tocilizumab administration intervals and lower prednisolone doses seemed pivotal for successful tocilizumab withdrawal while maintaining remission in patients with AOSD.

Tokyo , Japan , Hiroya-tamai , Division-of-rheumatology , Department-of-internal-medicine , Keio-university-school-of-medicine , Internal-medicine , Keio-university-school , Biologic-therapy , Iologics , Remission , Juvenile-rheumatoid-arthritis

FDA OKs First Interchangeable Humira Biosimilar

It is the tenth adalimumab biosimilar approved by the regulatory agency.

United-states , Australia , Canada , Robert-wessman , European-union , Teva-pharmaceuticals , Pfizer , Boehringer-ingelheim , Drug-administration , Biologic-therapy , Iologics , Biosimilars

Diagnosing Infection in Tocilizumab Users: What's Helpful?

Area under the curve for routine biomarkers distinguished infected and noninfected adults with inflammatory diseases.

Reims , Champagne-ardenne , France , Audrey-glatre , University-hospital-centre-reims , Rheumatoid-arthritis-ra , Heumatoid-arthritis-ra- , Juvenile-rheumatoid-arthritis , Uvenile-ra , Uvenile-idiopathic-arthritis , Temporal-arteritis , Iant-cell-arteritis

Juvenile Arthritis: Effects of Diagnosis and Coping

Juvenile arthritis (JA) is an umbrella term describing arthritis conditions that affect children under 16. According to the Arthritis Foundation, JA affects nearly 300,000 children in the United States. Most types of JA are autoimmune diseases where the immune system malfunctions and attacks healthy tissues.

Arthritis-foundation , Verywell-health , Treatment-plan , Arthritis-surgery , Children-with-juvenile , Juvenile-arthritis , Uvenile-idiopathic-arthritis , A , Utoimmune-diseases , Nflammation , Rthritis-foundation

Linking perinatal events to juvenile idiopathic arthritis-uveitis

Researchers investigate perinatal events associated with the manifestation of juvenile idiopathic arthritis and the development of JIA-uveitis.

Onjira-leibe , Scientific-reportsstudy , Arthritis , Uvenile-idiopathic-arthritis , Veitis , Utoantibodies , Ye , Mmunity , Mmunosuppression , Nflammation , Abor

FDA Approves TOFIDENCE™ (tocilizumab-bavi) a Biosimilar of ACTEMRA® developed by Bio-Thera Solutions

Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets, announced that its partner Biogen recently received notification from the United States Food and Drug Administration (FDA) on the approval of TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous formulation is approved for the treatment of moderately to severely active rheuma

Hong-kong , Guangzhou , Guangdong , China , Macau , Taiwan , United-states , Chinese , Wechat-bio-thera , Shengfeng-li , Biogen-inc , Bio-thera-solutions

Comparative genomic analysis between systemic juvenile rheumatoid arthritis and type 1 diabetes

Shared genetic markers and immune system involvement in sJRA and T1D.

China , Khongtham-shutterstock , Nuclear-factor , Scientific-reports , Gene-expression-omnibus , Medical-subject-headings , Mellitus-type , False-discovery-rate , Arthritis , Iabetes , Enomic , Uvenile-rheumatoid